Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Expected to Rise, HC Wainwright Analyst Says

Vanda Pharmaceuticals (NASDAQ:VNDA) had its price objective hoisted by equities researchers at HC Wainwright from $18.00 to $20.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 339.56% from the stock’s current price. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS and Q4 2026 earnings at $0.14 EPS.

Separately, StockNews.com assumed coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Stock Up 2.0 %

Vanda Pharmaceuticals stock opened at $4.55 on Tuesday. The firm has a market cap of $265.31 million, a PE ratio of -14.22 and a beta of 0.74. Vanda Pharmaceuticals has a 52-week low of $3.71 and a 52-week high of $6.75. The company’s 50 day moving average is $4.60 and its two-hundred day moving average is $4.83.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. The business had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. On average, equities research analysts anticipate that Vanda Pharmaceuticals will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Schonfeld Strategic Advisors LLC purchased a new stake in Vanda Pharmaceuticals during the 4th quarter worth about $1,296,000. Millennium Management LLC raised its position in shares of Vanda Pharmaceuticals by 67.4% during the 4th quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock worth $3,203,000 after acquiring an additional 269,183 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Vanda Pharmaceuticals during the fourth quarter worth approximately $1,221,000. Dimensional Fund Advisors LP lifted its stake in Vanda Pharmaceuticals by 10.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock worth $11,920,000 after purchasing an additional 227,428 shares during the last quarter. Finally, Monaco Asset Management SAM increased its stake in Vanda Pharmaceuticals by 92.8% in the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock valued at $1,879,000 after purchasing an additional 188,836 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.